Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
Rhea-AI Summary
Enlivex (Nasdaq: ENLV) received a Nasdaq notice that its ordinary shares failed to meet the $1.00 minimum bid price for 30 consecutive business days, triggering a compliance period.
Enlivex has 180 days, until November 9, 2026, to regain compliance, with a possible additional 180-day extension.
Positive
- Initial 180-day period, until November 9, 2026, to regain $1.00 bid compliance
- Potential additional 180-day extension if other Nasdaq Capital Market listing standards are met
- Notice has no immediate effect on Nasdaq listing or trading of ordinary shares
- Company can use tools such as a reverse stock split, if necessary, to cure deficiency
Negative
- Closing bid price stayed below $1.00 for 30 consecutive business days
- Failure to regain compliance could lead to Nasdaq delisting of ordinary shares
- Second 180-day compliance period is not guaranteed and depends on meeting other listing standards
- Potential need to effect a reverse stock split to restore minimum bid price
News Market Reaction – ENLV
In the May 18 session, ENLV declined 3.23%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Crypto listing update | Positive | +2.3% | RAIN treasury token listed on HTX, expanding access and liquidity. |
| Apr 28 | Treasury valuation update | Positive | -6.4% | Reported 78.82B+ RAIN tokens valued at $567M and option economics. |
| Apr 23 | Phase IIa data plans | Positive | +2.0% | Announcement of Allocetra Phase IIa data presentation at OARSI 2026. |
| Apr 21 | Trial approval | Positive | +0.3% | DKMA approval for global Phase 2b Allocetra osteoarthritis trial. |
| Apr 08 | Tokenized shares launch | Positive | +12.0% | Ondo launched ENLVon, a tokenized representation of Enlivex shares. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ENLV headlines have mostly been followed by positive price reactions, with only one notable divergence despite constructive news.
Over the past six weeks, Enlivex reported multiple developments spanning its RAIN token treasury and Allocetra program. A RAIN listing on HTX and a prior update valuing 78.8B+ tokens at $567M showed its digital-asset strategy, while tokenization of ENLV shares via Ondo and regulatory progress into global Phase 2b osteoarthritis trials highlighted capital-markets access and clinical advancement. Most of these updates saw positive 24-hour moves, framing today’s Nasdaq bid-price deficiency as a contrast to generally constructive recent news flow.
Key Terms
minimum bid price financial
reverse stock split financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Nes-Ziona, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that it has received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the closing bid price of the Company’s ordinary shares during the 30 consecutive business days prior to the date of the Notice did not meet the
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided with an initial period of 180 calendar days, or until November 9, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the ordinary shares must be at least
If the Company is unable to regain compliance by November 9, 2026, the Company may be eligible for an additional 180 calendar day compliance period to demonstrate compliance with the minimum bid price requirement. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary, and it must otherwise appear to Nasdaq that the Company is capable of curing the deficiency. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180 calendar day period, then Nasdaq will notify the Company that its ordinary shares are subject to delisting, at which time the Company would have an opportunity to appeal the delisting determination to a Hearings Panel.
The Company will monitor the closing bid price of its ordinary shares. Receipt of the Notice has no immediate effect on the Company’s Nasdaq listing or the trading of its ordinary shares, nor does receipt of the Notice have any effect on the Company’s business operations.
About Enlivex (Nasdaq: ENLV)
Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis.
In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the RAIN token, which is the token of the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.
ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Ltd.
shachar@enlivex.com
